Europe Next-Generation Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Targeted Therapy (Small Molecule Inhibitors), Immunotherapy Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) CAR-T Cell Therapy Cancer Vaccines, Gene Therapy, Cell Therapy (e.g., TILs, NK cells) ), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers (Leukemia, Lymphoma, Myeloma) ), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: Europe Next-Generation Cancer Therapeutics Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on Europe Next-Generation Cancer Therapeutics Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. Europe Next-Generation Cancer Therapeutics Market, By Therapy Type
   1. Introduction
      1. Market Size and Forecast, By Therapy Type
   2. Targeted Therapy (Small Molecule Inhibitors) 
      1. Market Size and Forecast, By Region
   3. Immunotherapy 
      1. Market Size and Forecast, By Region
      2. Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) 
         1. Market Size and Forecast, By Region
      3. CAR-T Cell Therapy 
         1. Market Size and Forecast, By Region
      4. Cancer Vaccines 
         1. Market Size and Forecast, By Region
   4. Gene Therapy 
      1. Market Size and Forecast, By Region
   5. Cell Therapy (e.g., TILs, NK cells) 
      1. Market Size and Forecast, By Region
   6. Antibody-Drug Conjugates (ADCs) 
      1. Market Size and Forecast, By Region
   7. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
      1. Market Size and Forecast, By Region
10. Europe Next-Generation Cancer Therapeutics Market, By Cancer Type
    1. Introduction
       1. Market Size and Forecast, By Cancer Type
    2. Lung Cancer 
       1. Market Size and Forecast, By Region
    3. Breast Cancer 
       1. Market Size and Forecast, By Region
    4. Colorectal Cancer 
       1. Market Size and Forecast, By Region
    5. Blood Cancers (Leukemia, Lymphoma, Myeloma) 
       1. Market Size and Forecast, By Region
    6. Prostate Cancer 
       1. Market Size and Forecast, By Region
    7. Brain Cancer (e.g., GBM) 
       1. Market Size and Forecast, By Region
    8. Pan-Tumor (Tumor-agnostic therapies)  
       1. Market Size and Forecast, By Region
11. Europe Next-Generation Cancer Therapeutics Market, By Modality
    1. Introduction
       1. Market Size and Forecast, By Modality
    2. Monotherapy 
       1. Market Size and Forecast, By Region
    3. Combination Therapy 
       1. Market Size and Forecast, By Region
       2. Immunotherapy + Targeted Drugs 
          1. Market Size and Forecast, By Region
       3. Chemotherapy + ADC 
          1. Market Size and Forecast, By Region
       4. mRNA + Checkpoint Inhibitors 
          1. Market Size and Forecast, By Region
12. Europe Next-Generation Cancer Therapeutics Market, By Route of Administration
    1. Introduction
       1. Market Size and Forecast, By Route of Administration
    2. Intravenous (IV) 
       1. Market Size and Forecast, By Region
    3. Oral 
       1. Market Size and Forecast, By Region
    4. Intratumoral / Localized 
       1. Market Size and Forecast, By Region
    5. Subcutaneous 
       1. Market Size and Forecast, By Region
13. Europe Next-Generation Cancer Therapeutics Market, By Mechanism of Action
    1. Introduction
       1. Market Size and Forecast, By Mechanism of Action
    2. Immune Activation (Checkpoint Inhibition)
       1. Market Size and Forecast, By Region
    3. Oncogene Targeting (e.g., BRAF, KRAS, EGFR) 
       1. Market Size and Forecast, By Region
    4. DNA Damage Response Modulators (e.g., PARP inhibitors) 
       1. Market Size and Forecast, By Region
    5. Tumor Microenvironment Modulatio
       1. Market Size and Forecast, By Region
    6. Apoptosis Induction 
       1. Market Size and Forecast, By Region
14. Europe Next-Generation Cancer Therapeutics Market, By End-User
    1. Introduction
       1. Market Size and Forecast, By End-User
    2. Specialized Cancer Hospitals  
       1. Market Size and Forecast, By Region
    3. Academic and Research Institutes 
       1. Market Size and Forecast, By Region
    4. Ambulatory Infusion Centers 
       1. Market Size and Forecast, By Region
    5. Homecare (for oral or SC delivery) 
       1. Market Size and Forecast, By Region
15. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. Europe
       1. Market Size and Forecast
          1. By Therapy Type
             1. Targeted Therapy (Small Molecule Inhibitors) 
             2. Immunotherapy 
             1. Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) 
             2. CAR-T Cell Therapy 
             3. Cancer Vaccines 
             3. Gene Therapy 
             4. Cell Therapy (e.g., TILs, NK cells) 
             5. Antibody-Drug Conjugates (ADCs) 
             6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
          2. By Cancer Type
             1. Lung Cancer 
             2. Breast Cancer 
             3. Colorectal Cancer 
             4. Blood Cancers (Leukemia, Lymphoma, Myeloma) 
             5. Prostate Cancer 
             6. Brain Cancer (e.g., GBM) 
             7. Pan-Tumor (Tumor-agnostic therapies)  
          3. By Modality
             1. Monotherapy 
             2. Combination Therapy 
             1. Immunotherapy + Targeted Drugs 
             2. Chemotherapy + ADC 
             3. mRNA + Checkpoint Inhibitors 
          4. By Route of Administration
             1. Intravenous (IV) 
             2. Oral 
             3. Intratumoral / Localized 
             4. Subcutaneous 
          5. By Mechanism of Action
             1. Immune Activation (Checkpoint Inhibition)
             2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR) 
             3. DNA Damage Response Modulators (e.g., PARP inhibitors) 
             4. Tumor Microenvironment Modulatio
             5. Apoptosis Induction 
          6. By End-User
             1. Specialized Cancer Hospitals  
             2. Academic and Research Institutes 
             3. Ambulatory Infusion Centers 
             4. Homecare (for oral or SC delivery) 
       2. United Kingdom
          1. By Therapy Type
             1. Targeted Therapy (Small Molecule Inhibitors) 
             2. Immunotherapy 
             1. Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) 
             2. CAR-T Cell Therapy 
             3. Cancer Vaccines 
             3. Gene Therapy 
             4. Cell Therapy (e.g., TILs, NK cells) 
             5. Antibody-Drug Conjugates (ADCs) 
             6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
          2. By Cancer Type
             1. Lung Cancer 
             2. Breast Cancer 
             3. Colorectal Cancer 
             4. Blood Cancers (Leukemia, Lymphoma, Myeloma) 
             5. Prostate Cancer 
             6. Brain Cancer (e.g., GBM) 
             7. Pan-Tumor (Tumor-agnostic therapies)  
          3. By Modality
             1. Monotherapy 
             2. Combination Therapy 
             1. Immunotherapy + Targeted Drugs 
             2. Chemotherapy + ADC 
             3. mRNA + Checkpoint Inhibitors 
          4. By Route of Administration
             1. Intravenous (IV) 
             2. Oral 
             3. Intratumoral / Localized 
             4. Subcutaneous 
          5. By Mechanism of Action
             1. Immune Activation (Checkpoint Inhibition)
             2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR) 
             3. DNA Damage Response Modulators (e.g., PARP inhibitors) 
             4. Tumor Microenvironment Modulatio
             5. Apoptosis Induction 
          6. By End-User
             1. Specialized Cancer Hospitals  
             2. Academic and Research Institutes 
             3. Ambulatory Infusion Centers 
             4. Homecare (for oral or SC delivery) 
       3. Germany
       4. France
       5. Spain
       6. Italy
       7. Russia
       8. Nordic
       9. Benelux
       10. Rest of Europe
16. Competitive Landscape, 2025
    1. Introduction
    2. Europe Next-Generation Cancer Therapeutics Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
17. Company Profile
    1. Roche
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. AstraZeneca
    3. Merck & Co.
    4. Bristol Myers Squibb
    5. Novartis
    6. Pfizer
    7. Johnson & Johnson
    8. Amgen
    9. Gilead Sciences
    10. Sanofi
    11. Daiichi Sankyo
    12. Takeda Pharmaceutical
    13. Bayer
    14. Ipsen
    15. BeiGene